Worldwide under-funding of stroke research

International Journal of Stroke

Volumn 2, Issue 2, 2007, Pages 80-84

  Pendlebury, Sarah T ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; LIPOPROTEIN A;

CANCER; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHLAMYDOPHILA PNEUMONIAE; CLINICAL RESEARCH; COST CONTROL; COST OF ILLNESS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG INDUSTRY; FUNDING; GOVERNMENT; HELICOBACTER PYLORI; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; RISK FACTOR; STROKE;

BIOMEDICAL RESEARCH; FINANCING, GOVERNMENT; HUMANS; INTERNATIONAL COOPERATION; RESEARCH SUPPORT AS TOPIC; STROKE; WORLD HEALTH;

EID: 34247873187     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2007.00126.x     Document Type: Review

References (21)

1. Sudlow CLM, Warlow CP, for the International Stroke Incidence Collaboration: Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. Stroke 1997; 28: 491-9.
2. MacDonald BK, Cockerell OC, Sander JWAS, Shorvon SD: The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665-76.
3. Murray CJL, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press, 1996.
4. Bonita R: Epidemiology of stroke. Lancet 1992; 339: 342-4.
5. Rothwell PM, Coull AJ, Silver LE et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366: 1773-83.
6. Wolfe CDA: The impact of stroke. Br Med Bull 2000; 56: 275-86.
7. Olesen J, Leonardi M: The burden of brain diseases in Europe. Eur J Neurol 2003; 10: 471-7.
8. Coronary Heart Disease Statistics: British Heart Foundation Statistics Database 1998. London: British Heart Foundation, 1998.
9. Stroke Care: Reducing the Burden of Disease. London: The Stroke Association, 1998.
10. Menken M, Munsat TL, Toole JF: The Global burden of disease study. Implications for neurology. Arch Neurol 2000; 57: 418-20.
11. Stegmayr B, Asplund K: Exploring the declining case fatality in acute stroke. Population-based observations in the northern Sweden MONICA project. J Intern Med 1996; 240: 143-9.
12. Janca A, Prilipko L, Costa e Silva JA: The World Health Organisation's global initiative on neurology and public health. J Neurol Sci 1997; 145: 1-2.
13. Broderick J: Gross under funding of stroke research. Lancet Neurol 2004; 3: 705-6.
14. Rothwell PM: The high cost of not fundinA stroke research: a comparison with heart disease and cancer. Lancet 2001; 357: 1612-16.
15. Pendlebury ST, Rothwell PM, Algra A et al. Under funding of stroke research: A Europe-wide problem. Stroke 2004; 35: 2368-71.
16. Toole JF, Toole WW: Federal funding for research in stroke and trauma - a clinical investigator's viewpoint. Stroke 1984; 15: 168-71.
17. Goldstein M: Federal funding for research in stroke and trauma - a clinical investigator's viewpoint. Stroke 1984; 15: 172-3.
18. Gross CP, Anderson GF, Power NR: The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999; 340: 1881-7.
19. Traystman RJ, Hademenos G: Increased funding for stroke research. Stroke 1999; 30: 1147.
20. Bhatia M, Rothwell PM: A systematic comparison of the quality and volume of published data available on novel risk factors for stroke versus coronary heart disease. Cerebrovasc Dis 2005; 20: 180-6.
21. Johnston SC, Rootenberg JD, Katrak D et al. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 2006; 367: 1319-27.